Crispr Therapeutics AG Form 4 insider transactions

CRISPR Therapeutics CEO Samarth Kulkarni reported gifting 30,000 common shares, reducing his direct beneficial ownership.

CRISPR Therapeutics CEO Samarth Kulkarni reported the vesting of 100,000 restricted stock units and a subsequent sale of 50,895 shares to cover tax obligations.

CRISPR Therapeutics CEO Samarth Kulkarni reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

CRISPR Therapeutics General Counsel James R. Kasinger acquired shares through RSU vesting and subsequently sold a portion to cover tax obligations.

CRISPR Therapeutics CEO Samarth Kulkarni was granted 49,500 stock options with an exercise price of $67.74, vesting over 48 months.

CRISPR Therapeutics' Chief Medical Officer, Naimish Patel, was granted stock options for 16,500 common shares with an exercise price of $67.74.

CRISPR Therapeutics' General Counsel and Secretary, James R. Kasinger, was granted 16,500 stock options with an exercise price of $67.74, vesting over 48 months.

CRISPR Therapeutics AG's Chief Financial Officer, Raju Prasad, was granted 16,500 stock options with an exercise price of $67.74, vesting over 48 months.

CRISPR Therapeutics CEO Samarth Kulkarni reported a charitable contribution of 6,000 common shares to a donor advised fund.

CRISPR Therapeutics CEO Samarth Kulkarni acquired 25,000 shares through RSU vesting and subsequently sold 13,081 shares to cover tax obligations.

CRISPR Therapeutics Director Douglas A. Treco increased his stake in the company by purchasing 20,000 common shares for approximately $1.14 million.

CRISPR Therapeutics AG Director Simeon George, through affiliated investment funds, acquired 989,812 common shares for approximately $51.5 million, increasing his indirect beneficial ownership to over 2 million shares.

Simeon George, a Director at CRISPR Therapeutics AG (CRSP), has been granted 13,000 stock options with an exercise price of $38.57, vesting over 12 months.

CRISPR Therapeutics AG Director Ali Behbahani was granted 13,000 stock options with an exercise price of $38.57, aligning his interests with the company's long-term performance.

Briggs Morrison, a Director at CRISPR Therapeutics AG, was granted 13,000 stock options with an exercise price of $38.57, aligning his interests with shareholder value.

CRISPR Therapeutics AG Director Douglas A. Treco was granted 13,000 stock options with an exercise price of $38.57, vesting over 12 months.

A recent SEC Form 4 filing reveals that Christian Rommel, a Director at CRISPR Therapeutics AG, was granted 13,000 stock options with an exercise price of $38.57.

CRISPR Therapeutics AG Director Harold Edward Fleming was granted 13,000 stock options with an exercise price of $38.57, vesting over 12 months.

CRISPR Therapeutics AG Director John Greene was granted 13,000 stock options with an exercise price of $38.57, vesting over 12 months.

CRISPR Therapeutics AG Director Sandesh Mahatme has acquired 13,000 stock options with an exercise price of $38.57, vesting over 12 months.

CRISPR Therapeutics AG Director Maria Fardis has been granted 13,000 stock options with an exercise price of $38.57, aligning her interests with shareholder value.

Katherine A. High, a Director at CRISPR Therapeutics AG, was granted 13,000 stock options with an exercise price of $38.57, vesting over 12 months.

CRISPR Therapeutics AG's Chief Financial Officer, Raju Prasad, was granted 20,000 Restricted Stock Units, vesting fully on May 30, 2028.

CRISPR Therapeutics AG's Chief Medical Officer, Naimish Patel, was granted 25,000 Restricted Stock Units, aligning executive compensation with long-term shareholder value.

CRISPR Therapeutics' Chief Medical Officer, Naimish Patel, reported the vesting of 10,000 restricted stock units and a subsequent sale of 3,932 shares to cover tax obligations.

CEO Samarth Kulkarni reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations, along with adjustments to holdings in a trust.

Julianne Bruno, COO of CRISPR Therapeutics, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Chief Financial Officer of CRISPR Therapeutics, Raju Prasad, sold shares to cover tax obligations following the vesting of restricted stock units.

James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Naimish Patel, Chief Medical Officer of CRISPR Therapeutics AG, reports the grant of stock options and restricted stock units.